{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:07:28Z","timestamp":1744344448703,"version":"3.40.4"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1038\/nrclinonc.2009.161-c1","type":"journal-article","created":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T11:17:18Z","timestamp":1267442238000},"page":"1-1","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab maintenance for follicular lymphoma"],"prefix":"10.1038","volume":"7","author":[{"given":"Liat","family":"Vidal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Gafter-Gvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Shpilberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFnrclinonc2009161c1_CR1","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrclinonc.2009.161","volume":"6","author":"DB Cheson","year":"2009","unstructured":"Cheson, D. B. The case against rituximab maintenance. Nat. Rev. Clin. Oncol. 6, 622\u2013624 (2009).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrclinonc2009161c1_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/jnci\/djn478","volume":"101","author":"L Vidal","year":"2009","unstructured":"Vidal, L.  et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J. Natl Cancer Inst. 101, 248\u2013255 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc2009161c1_CR3","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster, H.  et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progession-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J. Clin. Oncol. 27, 1607\u20131614 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009161c1_CR4","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/jco.2007.25.18_suppl.8004","volume":"25","author":"H Hochster","year":"2007","unstructured":"Hochster, H.  et al. Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: results from the ECOG\/CALGB intergroup E1496 trial. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I 25, 8004 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009161c1_CR5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/blood.V106.11.349.349","volume":"106","author":"H Hochster","year":"2005","unstructured":"Hochster, H., Weller, E., Gascoyne, R.  et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group [abstract]. Blood 106, 349 (2005).","journal-title":"Blood"},{"key":"BFnrclinonc2009161c1_CR6","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH van Oers","year":"2006","unstructured":"van Oers, M. H.  et al. Rituximab maintenance improves clinical outcome of relapsed\/refractory follicular non-Hodgkin's lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 108, 3295\u20133301 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc2009161c1_CR7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V112.11.309.309","volume":"112","author":"MHJ Van Oers","year":"2008","unstructured":"Van Oers, M. H. J.  et al. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study [abstract 836]. Blood 112, 309\u2013310 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009161c1_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/jnci\/djp257","volume":"101","author":"L Vidal","year":"2009","unstructured":"Vidal, L., Gafter-Gvili, A., Leibovici, L., Dreyling, M., Ghielmini, M., Shpilberg, O. Response: Re: Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized trials. J. Natl Cancer Inst. 101, 1289\u20131290 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc2009161c1_CR9","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini, M.  et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with weekly \u00d7 4 schedule. Blood 103, 4416\u20134423 (2004).","journal-title":"Blood"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2009.161-c1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2009.161-c1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2009.161-c1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T10:50:13Z","timestamp":1744282213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2009.161-c1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["BFnrclinonc2009161c1"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2009.161-c1","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"type":"print","value":"1759-4774"},{"type":"electronic","value":"1759-4782"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}